New chemotherapy delivery method for advanced ovarian cancer with abdominal spread

Plain-English translation of NCT07514494 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new way to deliver chemotherapy called pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with advanced ovarian cancer that has spread throughout the abdomen. The treatment uses a special laparoscopic procedure—a minimally invasive surgery using a thin camera—to spray chemotherapy directly into the abdominal cavity as a pressurized aerosol, which helps the medication reach cancer cells more effectively. This new delivery method is being combined with standard chemotherapy and surgery to see if it improves outcomes for women whose cancer has spread widely inside the abdomen.

Advanced ovarian cancer that spreads throughout the abdomen (called peritoneal carcinomatosis) is very difficult to treat, and standard chemotherapy and surgery alone don't always work well enough. This trial exists to see whether delivering chemotherapy directly to the abdominal cavity in this new way can better control the cancer while still allowing patients to receive all their other treatments.

Do you qualify?

You likely qualify if…

you are a woman aged 18 to 75 years old
you have been diagnosed with advanced ovarian cancer (FIGO stage IIIB or IIIC) with cancer spread throughout your abdomen
your ovarian cancer has been confirmed by a tissue sample (biopsy)
imaging tests (such as CT, ultrasound, or MRI) have shown cancer spread in your abdomen
you are in good enough overall health to safely undergo surgery and chemotherapy
you are able to follow the study procedures and give written informed consent

You likely don't qualify if…

you are older than 75 years of age or in very poor overall health
your cancer has spread outside the abdomen (such as to the lungs or other distant organs)
you have a specific type of ovarian cancer called mucinous carcinoma or another active cancer diagnosis
you have severe scarring (adhesions) inside your abdomen that would make surgery unsafe
you are pregnant, breastfeeding, or have a genetic mutation (BRCA1 or BRCA2)

What participation looks like

Participants will undergo several visits over several months combining minimally invasive diagnostic surgery, chemotherapy infusions, and major surgery. Some participants will receive the new pressurized aerosol chemotherapy three times during their treatment (at the beginning, midway through, and during their main surgery), while others will receive it only once during their main surgery. All participants receive standard intravenous chemotherapy and interval cytoreductive surgery, with additional imaging and tissue samples taken to monitor how well the treatment is working.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

Russia

Moscow Regional Oncological Dispensary, Balashikha